These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 23624357

  • 1. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
    Chengwei X, Xiaoli M, Yuan Z, Li P, Shengjiang W, Chao Y, Yunshan W.
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
    [Abstract] [Full Text] [Related]

  • 2. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 3. Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
    Fawzy MS, Mohammed EA, Ahmed AS, Fakhr-Eldeen A.
    Meta Gene; 2015 Jun; 4():73-84. PubMed ID: 25893174
    [Abstract] [Full Text] [Related]

  • 4. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
    Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA.
    Acta Cardiol; 2011 Aug; 66(4):483-8. PubMed ID: 21894805
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 6. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
    Kozian DH, Lorenz M, März W, Cousin E, Mace S, Deleuze JF.
    Thromb Haemost; 2010 May; 103(5):976-83. PubMed ID: 20216989
    [Abstract] [Full Text] [Related]

  • 7. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
    Orikaza CM, Morelli VM, Matos MF, Lourenço DM.
    Thromb Res; 2014 Jan; 133(1):120-4. PubMed ID: 24252537
    [Abstract] [Full Text] [Related]

  • 8. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP.
    Thromb Haemost; 2003 Jul; 90(1):92-100. PubMed ID: 12876631
    [Abstract] [Full Text] [Related]

  • 9. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
    de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW, Liver and Thrombosis Study Group.
    Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome.
    Tàssies D, Roqué M, Monteagudo J, Martorell T, Sionis A, Arzamendi D, Heras M, Reverter JC.
    Thromb Res; 2009 Nov; 124(5):614-8. PubMed ID: 19699511
    [Abstract] [Full Text] [Related]

  • 11. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 12. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
    Boffa MB, Koschinsky ML.
    Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
    [Abstract] [Full Text] [Related]

  • 13. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
    Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenço D, Morelli V, Maffei FH, Ferrari IC, Piccinato CE, Silva WA, Zago MA.
    Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
    [Abstract] [Full Text] [Related]

  • 14. +1040 C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitor gene and the risk of idiopathic recurrent fetal loss.
    Pruner I, Djordjevic V, Miljic P, Kovac M, Antonijevic N, Rakicevic L, Radojkovic D.
    Blood Coagul Fibrinolysis; 2010 Oct; 21(7):679-82. PubMed ID: 20729722
    [Abstract] [Full Text] [Related]

  • 15. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
    Sucker C, Hetzel GR, Farokhzad F, Dahhan F, Schmitz M, Kurschat C, Grabensee B, Maruhn-Debowski B, Zotz R, Scharf R.
    Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
    [Abstract] [Full Text] [Related]

  • 16. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
    Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P.
    Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
    [Abstract] [Full Text] [Related]

  • 17. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
    Stasko J, Hudecek J, Kubisz P.
    Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
    [Abstract] [Full Text] [Related]

  • 18. Levels of thrombin activatable fibrinolysis inhibitor in gestational diabetes mellitus.
    Gumus II, Kargili A, Karakurt F, Kasapoglu B, Derbent A, Kaygusuz I, Koca C, Sevgili S.
    Gynecol Endocrinol; 2013 Apr; 29(4):327-30. PubMed ID: 23327722
    [Abstract] [Full Text] [Related]

  • 19. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
    Hamdy M, Shaheen IA, Khallaf M, Selim YMM.
    Pediatr Blood Cancer; 2024 Jun; 71(6):e30959. PubMed ID: 38520679
    [Abstract] [Full Text] [Related]

  • 20. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
    Dusse LM, Cooper AJ, Lwaleed BA.
    Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.